Skip to main
  1. Stocks
  2. STAAR Surgical
  3. Forecast
STAA

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 13%
Hold 38%
Sell 0%
Strong Sell 13%

Bulls say

Staar Surgical is supported by a powerful China recovery, with 2Q’26 net sales of $93.5M rising 111% year over year and China revenue of $52.3M growing over 100% on continued EVO+ adoption, while ex-China sales still increased 6% despite Middle East-related EMEA softness. Profitability is also inflecting sharply, as adjusted EBITDA reached $20.0M with a 21.4% margin versus a loss in 2Q’25, helped by 74.5% gross margin, disciplined operating expense management, and a clean liquidity position of $181.5M in cash and investments with no debt. The leadership transition to permanent CEO Warren Foust further reduces uncertainty, and management’s confidence around demand outstripping supply, no distributor inventory build, and eventual normalization of tariff drag supports a constructive long-term outlook.

Bears say

Staar Surgical is facing a deteriorating competitive position in China as EyeBright’s domestically manufactured phakic lens launched in spring 2025 at roughly one-third the cost of STAA’s ICL, with clinicians viewing early quality as comparable and suggesting meaningful share loss once 6-12 months of follow-up data accumulates. The company’s core ICL franchise is also constrained by a cautious adoption cycle in young patients, where long-term biocompatibility data is essential, while one expert estimated EyeBright could take 10%-15% of the China ICL market near term and potentially 40% in coming years if results hold. More broadly, the addressable market appears structurally limited because LASIK remains the dominant refractive procedure due to lower cost, bilateral same-day treatment, and surgeon economics, leaving ICL as a niche option for patients who cannot undergo LASIK or PRK.

STAAR Surgical (STAA) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 13% recommend Buy, 38% suggest Holding, 0% advise Selling, and 13% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

STAAR Surgical (STAA) Analyst Forecast & Price Prediction

Get the latest STAAR Surgical (STAA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STAAR Surgical (STAA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 8 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


STAAR Surgical (STAA) Analyst Forecast & Price Prediction

Get the latest STAAR Surgical (STAA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in STAAR Surgical (STAA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover STAA stock data and trends